Why the study?
Does incorporating CYP4F2 and pooled rare variants of CYP2C9 into pharmacogenetic algorithms improve the estimation of therapeutic warfarin dose in patients on chronic therapy?
Does incorporating CYP4F2 and pooled rare variants of CYP2C9 into pharmacogenetic algorithms improve the estimation of therapeutic warfarin dose in patients on chronic therapy?
Incorporating CYP4F2 and pooled rare variants of CYP2C9 significantly improves the ability to estimate therapeutic warfarin dose compared to clinical factors alone.
No takes yet. Share an insight, caveat, or question.
Supports refining warfarin pharmacogenetic algorithms with CYP4F2 and rare variants; leaves open prospective outcome validation.
Sagrieya et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: